Skip to main content

Table 2 Meta-analysis of the association between each XPD gene polymorphism and NHL risk

From: Association of the Asp312Asn and Lys751Gln polymorphisms in the XPD gene with the risk of non-Hodgkin’s lymphoma: evidence from a meta-analysis

Variable

No. of studies

Sample size (cases/controls)

Homozygous

Heterozygous

Recessive

Dominant

Allele comparison

OR (95% CI)

P het

OR (95% CI)

P het

OR (95% CI)

P het

OR (95% CI)

P het

OR (95% CI)

P het

Asp312Asn polymorphism

AA vs. GG

GA vs. GG

AA vs. (GA + GG)

(GA + AA) vs. GG

A vs. G

All

6

3,095/3,306

1.11 (0.94-1.32)

0.718

1.00 (0.89-1.11)

0.935

1.12 (0.95-1.31)

0.368

1.02 (0.92-1.13)

0.426

1.04 (0.96-1.12)

0.717

Ethnicity

Caucasian

3

1,596/1,833

1.10 (0.88-1.37)

0.580

1.00 (0.87-1.16)

0.073

1.09 (0.89-1.34)

0.156

1.02 (0.89-1.17)

0.315

1.03 (0.93-1.14)

0.986

Asian

1

307/303

1.38 (0.31-6.23)

NA

1.39 (0.87-2.22)

NA

1.32 (0.29-5.95)

NA

1.39 (0.88-2.19)

NA

1.36 (0.89-2.07)

NA

Mixed

2

1,192/1,170

1.12 (0.86-1.46)

0.192

0.94 (0.79-1.12)

0.687

1.16 (0.90-1.50)

0.217

0.98 (0.83-1.15)

0.450

1.02 (0.90-1.15)

0.267

Source of the controls

PB

5

2,788/3,003

1.11 (0.94-1.32)

0.591

0.98 (0.88-1.09)

0.223

1.12 (0.95-1.31)

0.252

1.00 (0.91-1.12)

0.549

1.03 (0.95-1.11)

0.864

HB

1

307/303

1.38 (0.31-6.23)

NA

1.39 (0.87-1.22)

NA

1.32 (0.29-5.95)

NA

1.39 (0.88-2.19)

NA

1.36 (0.89-2.07)

NA

NHL subtype

DLBCL

4

726/2,170

1.00 (0.73-1.37)

0.829

0.98 (0.80-1.18)

0.667

1.01 (0.75-1.37)

0.669

1.02 (0.86-1.22)

0.463

0.99 (0.86-1.14)

0.998

FL

5

1,088/2,772

1.12 (0.88-1.42)

0.595

1.00 (0.85-1.17)

0.059

1.10 (0.88-1.38)

0.194

1.03 (0.89-1.20)

0.297

1.04 (0.93-1.16)

0.732

Lys751Gln polymorphism

CC vs. AA

AC vs. AA

C/C vs. (AC + AA)

(AC + CC) vs. AA

C vs. A

All

7

3,249/3,676

0.97 (0.83-1.15)

0.428

0.96 (0.86-1.06)

0.184

1.00 (0.86-1.16)

0.200

0.96 (0.87-1.06)

0.335

0.98 (0.91-1.05)

0.405

Ethnicity

Caucasian

3

1,666/1,848

0.88 (0.72-1.09)

0.305

0.99 (0.86-1.14)

0.255

0.88 (0.72-1.07)

0.137

0.96 (0.84-1.10)

0.482

0.95 (0.86-1.05)

0.522

Asian

2

381/659

1.85 (0.53-6.47)

0.823

1.15 (0.76-1.73)

0.159

1.81 (0.52-6.33)

0.777

1.20 (0.81-1.78)

0.184

1.23 (0.85-1.77)

0.232

Mixed

2

1,202/1,169

1.11 (0.85-1.44)

0.397

0.88 (0.74-1.05)

0.140

1.19 (0.93-1.52)

0.718

0.93 (0.79-1.09)

0.140

1.00 (0.89-1.13)

0.227

Source of the controls

PB

5

2,868/3,017

0.96 (0.82-1.13)

0.307

0.94 (0.84-1.05)

0.205

0.99 (0.85-1.15)

0.111

0.95 (0.85-1.05)

0.438

0.97 (0.90-1.04)

0.530

HB

2

381/659

1.85 (0.53-6.47)

0.823

1.15 (0.76-1.73)

0.159

1.81 (0.52-6.33)

0.777

1.20 (0.81-1.78)

0.184

1.23 (0.85-1.77)

0.232

NHL subtype

DLBCL

5

946/2,731

0.96 (0.74-1.24)

0.003

0.90 (0.76-1.07)

0.213

1.01 (0.79-1.29)

0.005

0.95 (0.81-1.11)

0.042

0.96 (0.85-1.08)

0.005

FL

6

1,227/3,322

0.87 (0.69-1.08)

0.522

0.95 (0.82-1.11)

0.234

0.88 (0.72-1.09)

0.227

0.95 (0.82-1.09)

0.448

0.93 (0.84-1.03)

0.681

  1. OR, odds ratio; CI, confidence interval; P het, P value for heterogeneity; NA, not applicable; DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma. Other abbreviations as in Table 1.